BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34383182)

  • 1. Dose predictions for [
    Ku A; Kondo M; Cai Z; Meens J; Li MR; Ailles L; Reilly RM
    EJNMMI Radiopharm Chem; 2021 Aug; 6(1):25. PubMed ID: 34383182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
    Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
    Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
    Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
    EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Biological Effectiveness (RBE) of [
    Boyle AJ; Cai Z; O'Brien S; Crick J; Angers S; Reilly RM
    Nucl Med Biol; 2023; 122-123():108367. PubMed ID: 37506639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Auger Electron-Emitting Radioimmunotherapy with [
    Facca VJ; Cai Z; Ku A; Georgiou CJ; Reilly RM
    Mol Pharm; 2023 Dec; 20(12):6407-6419. PubMed ID: 37983089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
    Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
    Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and preclinical studies of
    Lam K; Chan C; Reilly RM
    MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
    van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
    Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
    van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
    J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
    EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
    van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
    Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
    J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.